Enhancing Biopharma ROI With In-House Long-Read Sequencing

By Marie-Ange Kouassi, Scientific Content Marketing

This content is brought to you by Genedata, a Danaher Operating Company.

Long-read sequencing is transforming biopharmaceutical R&D by offering a deeper, more accurate view of genetic material than traditional short-read methods. Its ability to sequence long, native DNA and RNA molecules in a single pass enables detailed insights into complex regions, structural variants, and epigenetic modifications. These capabilities are proving especially valuable across biopharma workflows—from clone selection and cell line characterization to biosafety testing and advanced therapeutic development. As regulatory agencies increasingly endorse NGS-based approaches, long-read sequencing is emerging as a powerful multi-attribute method that can consolidate multiple assays into a single, efficient workflow. Yet implementing this technology in-house requires thoughtful navigation of data complexity, infrastructure demands, and bioinformatics expertise.

Explore how next-generation long-read platforms are reshaping quality control and accelerating decision-making across biopharma R&D.